1. Medtech Insight
  2. >>Archive

News In Brief

Boston Scientific touts stent wins. Biomet settles foreign bribery charges. Roche ups Illumina bid. Derma Sciences acquires MedEfficiency.

An analysis of two-year data from Boston Scientific Corp.’s PLATINUM Workhorse trial found a statistically significant reduction in recurrent ischemia requiring repeat revascularization procedures with the firm’s Promus Element everolimus-eluting platinum-chromium stent compared to everolimus-eluting cobalt-chromium stents (either Abbott’s Xience V or Boston’ Promus) between the first and second year of follow up. “This finding is potentially important, but must be confirmed by longer-term follow up,” said Gregg Stone, M.D., Columbia University, who presented the results March 25 at the American College of Cardiology meeting in Chicago. Also at ACC, researchers presented analyses from Boston Scientific’s PERSEUS and PLATINUM clinical trials, suggesting no cases of longitudinal stent compression with Promus Element. The firm has been challenged by anecdotal reports that the rare event is more common in its stent. (See Also see "Boston Scientific Downplays Stent Compression Concerns" - Medtech Insight, 24 October, 2011..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: 7-11 April 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.